RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy

International Journal of Cancer

Volumn 139, Issue 4, 2016, Pages 803-811

  Osumi, Hiroki ^a   Shinozaki, Eiji ^a   Suenaga, Mitsukuni ^a   Matsusaka, Satoshi ^a   Konishi, Tsuyoshi ^a   Akiyoshi, Takashi ^a   Fujimoto, Yoshiya ^a   Nagayama, Satoshi ^a   Fukunaga, Yosuke ^a   Ueno, Masashi ^a   Mise, Yoshihiro ^a   Ishizawa, Takeaki ^a   Inoue, Yosuke ^a   Takahashi, Yu ^a   Saiura, Akio ^a   Uehara, Hirohumi ^a   Mun, Mingyon ^a   Okumura, Sakae ^a   Mizunuma, Nobuyuki ^a   Miki, Yoshio ^b   Yamaguchi, Toshiharu ^a   more..

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

biomarker; metastasectomy of colon cancer; RAS mutation; repeat metastasectomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVOR; CODON; COLORECTAL CANCER; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LIVER METASTASIS; LOG RANK TEST; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS RESECTION; ONCOGENE K RAS; ONCOGENE RAS; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; WILD TYPE;

EID: 84976601620     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30106     Document Type: Article

References (25)

1. Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (mFOLFOX) with bevacizumab (BV) orcetximab (CET) for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon and rectum. J Clin Oncol 2014; 32(suppl):5s.
2. Heinemann V, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065–75.
3. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466–74.
4. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21:2396–402.
5. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. 2010 ASCO Annual Meeting, Abstract No. 3507. J Clin Oncol 2010; 28:18s.
6. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235:759–66.
7. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250:440–8.
8. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46:S22–31.
9. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 1996; 77:1254–62.
10. Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 2007; 50:478–88.
11. Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006; 13:668–76.
12. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247:125–35.
13. Hamaji M, Cassivi SD, Shen KR, et al. Is lymph node dissection required in pulmonary metastasectomy for colorectal adenocarcinoma? Ann Thorac Surg 94:1796–800.
14. Cho S, Song IH, Yang HC, et al. Prognostic factors of pulmonary metastasis from colorectal carcinoma. Interact Cardiovasc Thorac Surg 2013; 17:303–7.
15. Renaud S, Falcoz PE, Olland A, et al. The intrathoracic lymph node ratio seems to be a better prognostic factor than the level of lymph node involvement in lung metastasectomy of colorectal carcinoma. Interact Cardiovasc Thorac Surg 2015; 20:215–21.
16. Fukushima Y, Yanaka S, Murakami K, et al. High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer. Gan To Kagaku Ryoho 2011; 38:1825–35.
17. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626–34.
18. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101:1308–24.
19. Arrington AK, Heinrich EL, Lee W, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012; 13:12153–68.
20. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85:692–6.
21. Taieb J, Tabernero J, Mini E. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15:862–73.
22. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120:2316–24.
23. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012; 18:2257–68.
24. Renaud S, Romain B, Falcoz PE, et al. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer 2015; 112:720–8.
25. Margonis GA, Spolverato G, Kim Y, et al. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015.